Table IV.
Oncological outcomes after OPHL type I.
| Author (year) | No. of cases | T1 | T2 | T3 | T4 | N0 | N+ | R+ | Adjuvant RT or CH or CH-RT | Mean FU time (months) | OS (years) | DSS/ DFS (years) | Local control (months, years) | Regional control (years) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bron (2000) 24 | 69 | 20 | 40 | 9 | 5 | 60 | 9 | 8 | 11 (16%) | NA | 66.5% (5y) | 80.1% (5y) | 84% (5y) | NA |
| Karasalihoglu (2004) 29 | 68 | 8 | 45 | 10 | 5 | 60 | 8 | NA | 1 (2%) | 62 | 78.6% (5y) | 93.9% (5y) | 89.5% (5y) | 90.4% (5y) |
| Nakayama (2007) 13 | 32 | 2 | 12 | 16 | 2 | 28 | 4 | NA | NA | 28 | 61% (5y) | NA | 100% (28m) | NA |
| Goncalves (2010) 31 | 20 | 1 | 5 | 12 | 2 | 18 | 2 | 0 | 6 (30%) | 25 | 90% (5y) | 85% (5y) | NA | NA |
| Park (2011) 12 | 116 | NA | NA | NA | NA | 97 | 19 | 5 | 24 (21%) | NA | 66.6% (5y) | 72.1% (5y) | 88.7% (5y) | 85% (5y) |
| Topaloglu (2012) 32 | 30 | 0 | 13 | 17 | 0 | 4 | 26 | NA | 8 (27%) | 56.2 | NA | NA | NA | NA |
| Karabulut (2018) 15 | 20 | 4 | 6 | 10 | 0 | NA | NA | NA | 15 (75%) | 41 | 95% (5y) | 95% (5y) | NA | NA |
| Mesolella (2020) 34 | 35 | 0 | 9 | 21 | 5 | 29 | 6 | NA | NA | 51,4 | 83% (5y) | 76.3% (5y) | NA | NA |
| Gokmen (2020) 19 | 31 | NA | NA | NA | NA | NA | NA | NA | NA | 66 | 83.9% (5y) | 80.6% (5y) | NA | NA |
| NA: not available; RT: radiotherapy; CH: chemotherapy; FU: follow-up; OS: overall survival; DSS: disease-specific survival; DFS: disease-free survival. | ||||||||||||||